Opinion: Cancer researchers’ failure to disclose industry payments damages patient trust — and care
Financial ties with pharmaceutical and device companies can complicate relationships between physicians, researchers, and patients. These ties shouldn't be severed, but openly disclosed.
Treating cancer is one of the most difficult medical challenges of our time. In addition to requiring effective therapies and compassionate clinicians and caregivers, it demands trustworthy and transparent communication. A report in JAMA Internal Medicine that summarized payments from the drug and device industry to directors of National Cancer Institute-designated cancer centers underscores the need to develop more rigorous strategies for reporting and monitoring.
Though the report showed that slightly more than half of the directors did not receive industry payments in 2017, slightly less
